Hemophilia A

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

NCT01486927 | PHASE 2 | INTERVENTIONAL

This is an open-label, non-randomized, efficacy, safety and pharmacokinetic (PK) study comparing octocog alfa and rVIII-SingleChain. The study consists of three parts, a PK period (Part 1), a continuation of dosing safety and efficacy period (Part 2) and a safety, efficacy, and repeat PK period (Part 3) and also includes a surgical sub-study for subjects enrolled in Parts 2 and 3.

56 Sites

175 Participants

Recruiting

12 Years to 65 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Study Site

Sacramento,California,United States,95817

Study Site

San Diego,California,United States,92103

Study Site

Aurora,Colorado,United States,80045

Study Site

Hartford,Connecticut,United States,06106

Study Site

Miami,Florida,United States,33136

Study Site

Chicago,Illinois,United States,60612

Study Site

New Orleans,Louisiana,United States,70112

Study Site

Houston,Texas,United States,77030

Study Site

Milwaukee,Wisconsin,United States,53226

Study Site

Nedlands,Australia,WA6009

Study Site

Perth,Australia,WA6000

Study Site

Graz,Austria,8036

Study Site

Vienna,Austria,1090

Study Site

New Brunswick,Canada,E2L4L2

Study Site

Hradec Králové,Czech Republic,50005

Study Site

Berlin,Germany,10249

Study Site

Berlin,Germany,13353

Study Site

Bonn,Germany,53127

Study Site

Gießen,Germany,35392

Study Site

Hamburg,Germany,20095

Study Site

Hannover,Germany,30159

Study Site

Heidelberg,Germany,69123

Study Site

Debrecen,Hungary,H-4032

Study Site

Florence,Italy,50134

Study Site

Milan,Italy,20122

Study Site

Padova,Italy,35123

Study Site

Padova,Italy,35128

Study Site

Torino,Italy,10126

Study Site

Kashihara, Nara,Japan

Study Site

Kitakyushu, Fukuoka,Japan

Study Site

Nagoya,Japan,466-85660

Study Site

Nishinomiya, Hyogo,Japan

Study Site

Okayama,Japan,710-8602

Study Site

Saitama,Japan

Study Site

Suginami-ku, Tokyo,Japan

Study Site

Tokyo,Japan,160-0023

Study Site

Beirut,Lebanon

Study Site

Kuala Lumpur,Malaysia,50400

Study Site

Utrecht,Netherlands,3584CX

Study Site

Cebu City,Philippines,6000

Study Site

Davao City,Philippines,8000

Study Site

Wroclaw,Silesia,Poland,50-367

Study Site

Gdansk,Poland,80-952

Study Site

Krakow,Poland,31-501

Study Site

Bucharest,Romania,011026

Study Site

Barnaul,Russian Federation,656038

Study Site

Kemerovo,Russian Federation,650066

Study Site

Cape Town,South Africa,7295

Study Site

Johannesburg,South Africa,2193

Study Site

Barcelona,Spain

Study Site

La Coruna,Spain

Study Site

Valencia,Spain,46026

Study Site

Dnipropetrovsk,Ukraine,49102

Study Site

Donetsk,Ukraine,830045

Study Site

Lviv,Ukraine,79044

Study Site

London,United Kingdom,NW32QG

Study Eligibility Criteria

Inclusion Criteria

* Diagnosis of severe hemophilia A defined as \<1% FVIII:C documented in medical records.
* Males between 18 and 65 years of age (Parts 1 and 2).
* Males between 12 and 65 years of age (Part 3).
* Subjects who have received or are currently receiving FVIII products (plasma-derived and/or recombinant FVIII) and have had \>150 exposure days (EDs) with a FVIII product
* Written informed consent for study participation obtained before undergoing any study specific procedures.

Exclusion Criteria

* Any history of or current FVIII inhibitors
* Any first order family history of FVIII inhibitors
* Use of an Investigational Medicinal Product within 30 days prior to the first rVIII-SingleChain administration.
* Administration of any cryoprecipitate, whole blood or plasma within 30 days prior to administration of rVIII-SingleChain or reference product.
* Known hypersensitivity (allergic reaction or anaphylaxis) to any FVIII product or hamster protein.
* Any known congenital or acquired coagulation disorder other than congenital FVIII deficiency.
* Platelet count \< 100,000/µL at screening.
* Human immunodeficiency virus (HIV) positive subjects with a CD4 count \< 200/mm3, in their medical history or at screening if available results are older than one year. (HIV positive subjects may participate in the study and antiviral therapy are permitted, at the discretion of the Investigator).
* Subject currently receiving IV immunomodulating agents such as immunoglobulin or chronic systemic corticosteroid treatment.
* Subject with serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) values \> 5 times (x) the upper limit of normal (ULN) at Screening.
* Subjects with serum creatinine values \> 2 x ULN at Screening.
* Evidence of thrombosis, including deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction and arterial embolus within 3 months prior to Day 1.
* Experienced life-threatening bleeding episode or had major surgery or an orthopedic surgical procedure during the 3 months prior to Day 1.

Additional Studies

Additional studies can be found at ClinicalTrials.gov